Skip to main content
Citation Number
Brief of the Federal Trade Commission as amicus curiae before the United States District Court for the Eastern District of Pennsylvania, addressing the question of whether reformulations of a branded company’s products that offer patients little or no therapeutic advantages – also known as “product-switching” or “product-hopping” – obstructs meaningful competition by generic drug companies and thus, constitutes exclusionary conduct.